Travere Presents Data Reinforcing Clinical Benefit Of FILSPARI In IgAN
Spartacus study, protect open. T ravere therapeutics (tvtx) presented new data further demonstrating the clinical benefit of filspari in iga nephropathy and reinforcing its potential in focal segmental. View full press release. Travere therapeutics to present abstracts at american society of nephrology (asn) kidney week 2024. Travere therapeutics to report third quarter 2024.
Presented new data further demonstrating the clinical benefit of filspari (sparsentan) in iga nephropathy (igan) and reinforcing its. Upcoming data presentations underscore the potential for filspari to become a foundational treatment for igan and travere’s leadership and commitment to innovation in rare.